Key terms
About GMAB
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GMAB news
Apr 16
8:21pm ET
Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Genmab (GMAB)
Apr 16
10:27am ET
Genmab Reports Strong Q1 Sales of DARZALEX
Apr 15
9:05pm ET
Genmab Advances Share Buy-back Program
Apr 09
7:35am ET
Truist Financial Keeps Their Buy Rating on Genmab (GMAB)
Apr 08
2:28pm ET
Genmab Advances Share Buy-back Program
Apr 08
3:50am ET
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), AbbVie (ABBV) and Immunome (IMNM)
Apr 04
10:30am ET
Analysts’ Top Healthcare Picks: Paragon 28 (FNA), Genmab (GMAB)
Apr 03
2:23pm ET
Genmab price target lowered to DKK 2,750 from DKK 2,800 at UBS
Apr 03
7:49am ET
M&A News: Genmab (NASDAQ:GMAB) Is Acquiring ProfoundBio for $1.8B
Apr 03
6:59am ET
Genmab Expands Oncology Reach with ProfoundBio Buyout
Apr 03
6:06am ET
Genmab acquires ProfoundBio for $1.8B in cash
Apr 02
10:28am ET
Genmab A/S Advances Its Share Buy-back Program
Mar 26
8:45am ET
Truist Financial Remains a Buy on Genmab (GMAB)
Mar 25
2:57pm ET
Genmab Launches Multi-Billion Share Buy-back
Mar 21
3:57pm ET
Genmab A/S Announces Share Capital and Warrant Updates
Mar 18
5:29pm ET
Genmab Completes Share Buy-Back Program
Mar 15
12:03pm ET
JPMorgan biotech/pharma analysts hold an analyst/industry conference call
Mar 06
6:40am ET
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Springworks Therapeutics (SWTX) and Genmab (GMAB)
Mar 01
7:35am ET
Truist Financial Reaffirms Their Buy Rating on Genmab (GMAB)
Feb 27
7:49am ET
AbbVie’s epcoritamab granted priority review by FDA in follicular lymphoma
Feb 27
7:48am ET
Genmab, AbbVie announce FDA priority review for sBLA
Feb 23
5:17am ET
Genmab upgraded to Outperform from Market Perform at BMO Capital
Feb 22
9:25pm ET
Genmab (GMAB) Gets a Buy from Truist Financial
Feb 21
2:49pm ET
Genmab price target lowered to DKK 2,400 from DKK 2,500 at RBC Capital
Feb 20
8:14am ET
Genmab price target lowered to $50 from $54 at Truist
Feb 20
6:30am ET
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), BioMarin Pharmaceutical (BMRN) and Greenwich LifeSciences (GLSI)
Feb 15
8:03am ET
Analysts Conflicted on These Healthcare Names: Genmab (GMAB), cbdMD (YCBD) and SAGE Therapeutics (SAGE)
Feb 15
7:10am ET
BMO Capital Reaffirms Their Hold Rating on Genmab (GMAB)
Feb 14
11:43am ET
Genmab initiating share buy-back program for up to 190,000 shares
Feb 13
5:22am ET
Maintaining Hold on Genmab: Balancing Darzalex Success with GEN3014’s Uncertain Future and Competitive Market Risks
Feb 02
6:46am ET
Genmab, Pfizer: EMA validates for review MAA of tisotumab vedotin
No recent press releases are available for GMAB
GMAB Financials
Key terms
Ad Feedback
GMAB Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GMAB Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
